Home › Regeneron Pharmaceuticals Given "Outperform" Rating at RBC Capital
 

Keywords :   


Regeneron Pharmaceuticals Given "Outperform" Rating at RBC Capital

2015-06-06 21:12:59| Biotech - Topix.net

REGN has been the subject of a number of other recent research reports. Analysts at Piper Jaffray reiterated a "neutral" rating and set a $484.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 21st.

Tags: rating capital pharmaceuticals rbc

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Graphics
02.11Tropical Storm Lane Wind Speed Probabilities Number 5
02.11Tropical Storm Lane Forecast Advisory Number 5
02.11Tropical Storm Lane Public Advisory Number 5
02.11Summary for Tropical Storm Lane (EP3/EP132024)
02.11Subtropical Storm Patty Forecast Discussion Number 3
02.11Subtropical Storm Patty Wind Speed Probabilities Number 3
More »